ADC Licensing, Partnering & Investment Session
Time: 3:00 pm
day: Pre-Conference Seminar Day Pt 2
Details:
It’s no secret that ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking. The total value of ADCs peaked at $167 billion in 2023, representing rampant billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond, and a bulk of Series A VC transactions highlighting a boom of new ADC companies forming.
As the leaders of the global pharmaceutical world look for a piece of the ADC pie, it is crucial to understand what innovation, data and risktaking criteria are fuelling the partnerships, licensing deals, and investment amongst ADC stakeholders.
Exclusively designed for search and evaluation, early innovation, and business development leads, C-level biotech leaders, and VC biopharma investors, join to be part of an insightful panel session followed by a unique networking space to foster new relationships for ADC collaboration, partnerships and investment ahead of the main conference days.
Register your interest when you sign up to attend the conference, then look out for an email to secure your spot!
Panel Discussion Highlights:
• Breaking down big pharma’s heavy investment into ADCs: what is the reasoning and level of risk behind recent mergers and acquisitions (M&As), and licensing deals?
• Laying out the lessons learnt from recent big pharma licensing and M&As – what can we expect after the blockbuster deals?
• Understanding the out-licensing perspective to breakdown required data, level of risk, and differentiating factors when from recent ADC partnerships and collaborations
• Taking a step back and evaluating the global state of the ADC field – what are predictions for where the ADC field will be in 3-5 years?
• Discussing how biotechs can be best positioned to stay ahead of the market innovation
